I-Mab and Junshi join forces on CD73/PD-1 combo development



China-based biotechs I-Mab Biopharma (Shanghai) Co., Ltd, and Shanghai Junshi biosciences Co., Ltd, have agreed to work together on a clinical study for I-Mab’s CD73 antibody TJD5 and Junshi’s programmed death-1 (PD-1) inhibitor toripalimab as a combination therapy in China. The pairing is expected to produce synergistic effects that boost the efficacy of tumor immunotherapy.

TJD5 is an in-house developed CD73 antibody that is the subject of ongoing Phase I clinical trials in the US in advanced solid tumor patients. Meanwhile, toripalimab is the subject of 30 ongoing studies across 14 different cancer indications, and was the first domestic PD-1 mAb to be approved in China at the end of 2018. Previous studies have shown that CD73 blockade in combination with PD-1 or CTLA-4 antibodies can enhance the therapeutic effect of checkpoint inhibitors and produce synergistic effects.


Reference:

Related news
China’s Shanghai Junshi Biosciences Co., Ltd (HKEX.1877) announced the enrollment of the 150 volunteers planned for its clinical study POLARIS-03 for Tuoyi (toripalimab), the firm’s first commercial product and which became the first domestically developed PD-1 drug to gain approval in China in December 2018.
China-based firms Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Shanghai Junshi biosciences Co., Ltd, and Innovent Biologics Inc., all presented clinical trial data for pipeline and on-market products at the World Conference on Lung Cancer (WCLC) 2019 this week.
Shanghai Junshi Biosciences Co., Ltd (HKEX.1877) released H1’19 financial results for 2019, including market performance details for Tuoyi (toripalimab), the firm’s first commercial product and the first domestically developed PD-1 drug to gain approval in China in December 2018.
China’s Jiangsu Hengrui Medicine Co., Ltd (600276.SH) picked up approvals from the National Medical Products Administration (NMPA) to carry out a Phase II clinical trial for pyrotinib maleate, a tyrosine kinase inhibitor (TKI), in advanced non-small cell lung adenocarcinoma with human epidermal growth factor receptor (HER2) mutation.
  • 1566961874124
  • China
  • Drug
Chinese firms Haihe Biopharma and Shanghai Junshi Biosciences Co., Ltd, are expanding their existing relationship to jointly explore the safety, tolerability, and effectiveness of the combination therapy glumetinib + toripalimab in treating multiple solid tumors.
Recent news
A study carried out by investigators at Brazil’s Oswaldo Cruz Foundation (Fiocruz) estimated the coping costs for the caretakers of minors with one of three selected rare diseases.
Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) this week ruled that all medical products that contain active pharmaceutical ingredients (APIs) that require bioequivalence tests must submit applications for these studies within 180 days.
Austria-based Themis is set to carry out a Phase III clinical trial (CT) on its chikungunya vaccine candidate.
  • 1568979876836
  • Mexico,Colombia,Guatemala,Dominican Republic,Chile,Puerto Rico ,Nicaragua,Guyana,Brazil,Cuba,Belize,Argentina,Paraguay,Ecuador ,Costa Rica,Peru,El Salvador,Panama,Haiti,Uruguay,Venezuela,Bolivia ,Honduras
  • Drug, Company
China’s leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc., (NASDAQ: CBPO) is once again being targeted by a consortium of investors in a potential USD 4.59 billion buyout deal that would take the firm private.
Suzhou-based biotech CStone Pharmaceuticals (HKEX.2616) announced that the GEMSTONE-101 cohort study for anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) CS1001 combined with cisplatin plus fluorouracil (CF) therapy in esophagus squamous cell carcinoma (ESCC) has yielded a 77.8% objective response rate (ORR) with good safety.
Shenzhen Chipscreen Biosciences Co., Ltd, (SH.688321) announced acceptance for review from the National Medical Products Administration (NMPA) in relation to a new drug application (NDA) filed for hypoglycemic drug chiglitazar (Bilessglu).
A draft law presented this week to Peru’s unicameral Congress by the New Peru (Nuevo Perú) minority party would force medics to prescribe generic medicines as a primary choice and originator drugs as a second alternative.
Analytics Snapshot


Analytics Snapshot